Inclusion Criteria:

- Provision of informed consent prior to any study specific procedures

- Female or male aged 18 years and over

- Previously confirmed histological diagnosis of unresectable, locally advanced or
metastatic hereditary or sporadic MTC. Documentation must be provided in patient's
medical chart

- WHO or ECOG Performance status 0-2

- Negative pregnancy test (urine or serum) for female patients of childbearing
potential

Exclusion Criteria:

- Unstable brain metastases or spinal cord compression that require treatment, unless
treated at least 4 weeks before first dose and stable without steroid treatment for
10 days

- Major surgery within 4 weeks before randomization

- The last dose of prior chemotherapy received less than 3 weeks prior to randomization

- Radiation therapy not completed prior to the first dose of vandetanib

- Significant cardiac event, superior vena cava syndrome, NYHA classification of heart
disease ≥2, within 12 weeks before randomization, or presence of cardiac disease that
in the opinion of the Investigator increases risk of ventricular arrhythmia

- Creatinine clearance <30 ml/min (calculated by Cockcroft-Gault formula),Patients with
moderate renal impairment, defined as creatinine clearance ≥30 to <50 ml/min, must
start vandetanib at a reduced dose of 200 mg